Clear, engaging, and practical updates on clinical psychiatry. Hosted by Chris Aiken, MD, and Kellie Newsome, PMHNP.
With two medications approved for tardive dyskinesia, how do you choose between them? And how does anyone afford their $80-140,000 a year price tag? We'll...
With two medications approved for tardive dyskinesia, how do you choose between them? And how does anyone afford their $80-140,000 a year price tag? We'll...
Esketamine (Spravato) was approved in 2019 for treatment resistant depression, but the medicine quickly gathered controversy about its long-term safety....
Esketamine (Spravato) was approved in 2019 for treatment resistant depression, but the medicine quickly gathered controversy about its long-term safety....
Esketamine (Spravato) was approved in 2019 for treatment resistant depression, but the medicine quickly gathered controversy about its long-term safety....